• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 1-A/A filed by Medicus Pharma Ltd.

    2/27/25 9:28:12 PM ET
    $MDCX
    Get the next $MDCX alert in real time by email
    schemaVersion:
    Form 1-A Issuer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 1-A
    REGULATION A OFFERING STATEMENT
    UNDER THE SECURITIES ACT OF 1933
    OMB APPROVAL


    FORM 1-A

    OMB Number:  3235-0286


    Estimated average burden hours per response: 608.0

    1-A: Filer Information

    Issuer CIK
    0001997296 
    Issuer CCC
    XXXXXXXX 
    DOS File Number
     
    Offering File Number
    024-12573 
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST
    Would you like a Return Copy? Checkbox not checked
    Notify via Filing Website only? Checkbox not checked
    Since Last Filing? Checkbox not checked

    Submission Contact Information

    Name
     
    Phone
     
    E-Mail Address
     

    1-A: Item 1. Issuer Information

    Issuer Infomation

    Exact name of issuer as specified in the issuer's charter

    Medicus Pharma Ltd. 

    Jurisdiction of Incorporation / Organization

    ONTARIO, CANADA  

    Year of Incorporation

    2008 

    CIK

    0001997296 

    Primary Standard Industrial Classification Code

    PHARMACEUTICAL PREPARATIONS 

    I.R.S. Employer Identification Number

    98-1778211 

    Total number of full-time employees

    12 

    Total number of part-time employees

    0 

    Contact Infomation

    Address of Principal Executive Offices

    Address 1

    300 CONSHOHOCKEN STATE RD., 

    Address 2

    SUITE 200 

    City

    W. CONSHOHOCKEN 

    State/Country

    PENNSYLVANIA  

    Mailing Zip/ Postal Code

    19428 

    Phone

    610-540-7515 

    Provide the following information for the person the Securities and Exchange Commission's staff should call in connection with any pre-qualification review of the offering statement.

    Name

    Christopher J. Cummings 

    Address 1

     

    Address 2

     

    City

     

    State/Country

     

    Mailing Zip/ Postal Code

     

    Phone

     

    Provide up to two e-mail addresses to which the Securities and Exchange Commission's staff may send any comment letters relating to the offering statement. After qualification of the offering statement, such e-mail addresses are not required to remain active.

    Financial Statements

    Use the financial statements for the most recent period contained in this offering statement to provide the following information about the issuer. The following table does not include all of the line items from the financial statements. Long Term Debt would include notes payable, bonds, mortgages, and similar obligations. To determine "Total Revenues" for all companies selecting "Other" for their industry group, refer to Article 5-03(b)(1) of Regulation S-X. For companies selecting "Insurance", refer to Article 7-04 of Regulation S-X for calculation of "Total Revenues" and paragraphs 5 and 7 of Article 7-04 for "Costs and Expenses Applicable to Revenues".

    Industry Group (select one) Radio button not checked Banking Radio button not checked Insurance Radio button checked Other

    Balance Sheet Information

    Cash and Cash Equivalents

    $ 5306159.00 

    Investment Securities
    $ 0.00 
    Total Investments

    $  

    Accounts and Notes Receivable

    $ 0.00 

    Loans

    $  

    Property, Plant and Equipment (PP&E):

    $ 0.00 

    Property and Equipment

    $  

    Total Assets

    $ 5720909.00 

    Accounts Payable and Accrued Liabilities

    $ 1879834.00 

    Policy Liabilities and Accruals

    $  

    Deposits

    $  

    Long Term Debt

    $ 0.00 

    Total Liabilities

    $ 2228805.00 

    Total Stockholders' Equity

    $ 3492104.00 

    Total Liabilities and Equity

    $ 5720909.00 

    Statement of Comprehensive Income Information

    Total Revenues

    $ 0.00 

    Total Interest Income

    $  

    Costs and Expenses Applicable to Revenues

    $ 8830197.00 

    Total Interest Expenses

    $  

    Depreciation and Amortization

    $ 78395.00 

    Net Income

    $ -8880935.00 

    Earnings Per Share - Basic

    $ -0.31 

    Earnings Per Share - Diluted

    $ -0.31 

    Name of Auditor (if any)

    EisnerAmper LLP 

    Outstanding Securities

    Common Equity

    Name of Class (if any) Common Equity

    Common shares, no par value 

    Common Equity Units Outstanding

    11922561 

    Common Equity CUSIP (if any):

    58471K202 

    Common Equity Units Name of Trading Center or Quotation Medium (if any)

    The Nasdaq Capital Market,The TSX Venture Exchange 

    Common Equity

    Name of Class (if any) Common Equity

    Public Warrants 

    Common Equity Units Outstanding

    1115500 

    Common Equity CUSIP (if any):

    58471K111 

    Common Equity Units Name of Trading Center or Quotation Medium (if any)

    The Nasdaq Capital Market 

    Common Equity

    Name of Class (if any) Common Equity

    Options 

    Common Equity Units Outstanding

    1185000 

    Common Equity CUSIP (if any):

    N/A 

    Common Equity Units Name of Trading Center or Quotation Medium (if any)

    N/A 

    Preferred Equity

    Preferred Equity Name of Class (if any)

     

    Preferred Equity Units Outstanding

    0 

    Preferred Equity CUSIP (if any)

     

    Preferred Equity Name of Trading Center or Quotation Medium (if any)

     

    Debt Securities

    Debt Securities Name of Class (if any)

     

    Debt Securities Units Outstanding

    0 

    Debt Securities CUSIP (if any):

     

    Debt Securities Name of Trading Center or Quotation Medium (if any)

     

    1-A: Item 2. Issuer Eligibility

    Issuer Eligibility

    Check this box to certify that all of the following statements are true for the issuer(s)

    Checkbox checked

    • Organized under the laws of the United States or Canada, or any State, Province, Territory or possession thereof, or the District of Columbia.
    • Principal place of business is in the United States or Canada.
    • Not subject to section 13 or 15(d) of the Securities Exchange Act of 1934.
    • Not a development stage company that either (a) has no specific business plan or purpose, or (b) has indicated that its business plan is to merge with an unidentified company or companies.
    • Not an investment company registered or required to be registered under the Investment Company Act of 1940.
    • Not issuing fractional undivided interests in oil or gas rights, or a similar interest in other mineral rights.
    • Not issuing asset-backed securities as defined in Item 1101 (c) of Regulation AB.
    • Not, and has not been, subject to any order of the Commission entered pursuant to Section 12(j) of the Exchange Act (15 U.S.C. 78l(j)) within five years before the filing of this offering statement.
    • Has filed with the Commission all the reports it was required to file, if any, pursuant to Rule 257 during the two years immediately before the filing of the offering statement (or for such shorter period that the issuer was required to file such reports).

    1-A: Item 3. Application of Rule 262

    Application Rule 262

    Check this box to certify that, as of the time of this filing, each person described in Rule 262 of Regulation A is either not disqualified under that rule or is disqualified but has received a waiver of such disqualification.

    Checkbox checked

    Check this box if "bad actor" disclosure under Rule 262(d) is provided in Part II of the offering statement.

    Checkbox not checked

    1-A: Item 4. Summary Information Regarding the Offering and Other Current or Proposed Offerings

    Summary Infomation

    Check the appropriate box to indicate whether you are conducting a Tier 1 or Tier 2 offering Radio button not checked Tier1 Radio button checked Tier2
    Check the appropriate box to indicate whether the financial statements have been audited Radio button not checked Unaudited Radio button checked Audited
    Types of Securities Offered in this Offering Statement (select all that apply)
    Checkbox checkedEquity (common or preferred stock) 
    Checkbox checkedOption, warrant or other right to acquire another security 
    Checkbox checkedSecurity to be acquired upon exercise of option, warrant or other right to acquire security 
    Does the issuer intend to offer the securities on a delayed or continuous basis pursuant to Rule 251(d)(3)? Radio button checked Yes Radio button not checked No
    Does the issuer intend this offering to last more than one year? Radio button checked Yes Radio button not checked No
    Does the issuer intend to price this offering after qualification pursuant to Rule 253(b)? Radio button checked Yes Radio button not checked No
    Will the issuer be conducting a best efforts offering? Radio button checked Yes Radio button not checked No
    Has the issuer used solicitation of interest communications in connection with the proposed offering? Radio button not checked Yes Radio button checked No
    Does the proposed offering involve the resale of securities by affiliates of the issuer? Radio button not checked Yes Radio button checked No
    Number of securities offered
    2222222 
    Number of securities of that class outstanding
    11922561 

    The information called for by this item below may be omitted if undetermined at the time of filing or submission, except that if a price range has been included in the offering statement, the midpoint of that range must be used to respond. Please refer to Rule 251(a) for the definition of "aggregate offering price" or "aggregate sales" as used in this item. Please leave the field blank if undetermined at this time and include a zero if a particular item is not applicable to the offering.

    Price per security
    $ 5.5000 
    The portion of the aggregate offering price attributable to securities being offered on behalf of the issuer
    $ 12222221.00 
    The portion of the aggregate offering price attributable to securities being offered on behalf of selling securityholders
    $ 0.00 
    The portion of the aggregate offering price attributable to all the securities of the issuer sold pursuant to a qualified offering statement within the 12 months before the qualification of this offering statement
    $ 0.00 
    The estimated portion of aggregate sales attributable to securities that may be sold pursuant to any other qualified offering statement concurrently with securities being sold under this offering statement
    $ 0.00 
    Total (the sum of the aggregate offering price and aggregate sales in the four preceding paragraphs)
    $ 12222221.00 

    Anticipated fees in connection with this offering and names of service providers

    Underwriters - Name of Service Provider
    Underwriters - Fees
    $  
    Sales Commissions - Name of Service Provider
    Maxim Group LLC
    Sales Commissions - Fee
    $ 916667.00 
    Finders' Fees - Name of Service Provider
    Finders' Fees - Fees
    $  
    Accounting or Audit - Name of Service Provider
    MNP LLP
    Accounting or Audit - Fees
    $ 100000.00 
    Legal - Name of Service Provider
    Paul, Weiss, Rifkind, Wharton and Garrison LLP; Bennett Jones LLP
    Legal - Fees
    $ 500000.00 
    Promoters - Name of Service Provider
    Promoters - Fees
    $  
    Blue Sky Compliance - Name of Service Provider
    Blue Sky Compliance - Fees
    $  
    CRD Number of any broker or dealer listed:
    000120708 
    Estimated net proceeds to the issuer
    $ 10555554.00 
    Clarification of responses (if necessary)
    Securities offered consists of 2,222,222 units, each consisting of one common share and one warrant. The issuer has 11,922,561 common shares outstanding prior to the offering. No warrants of the class being offered are outstanding prior to the offering.
     

    1-A: Item 5. Jurisdictions in Which Securities are to be Offered

    Jurisdictions in Which Securities are to be Offered

    Using the list below, select the jurisdictions in which the issuer intends to offer the securities

    Selected States and Jurisdictions

    ALABAMA
    ALASKA
    ARIZONA
    ARKANSAS
    CALIFORNIA
    COLORADO
    CONNECTICUT
    DELAWARE
    DISTRICT OF COLUMBIA
    FLORIDA
    GEORGIA
    HAWAII
    IDAHO
    ILLINOIS
    INDIANA
    IOWA
    KANSAS
    KENTUCKY
    LOUISIANA
    MAINE
    MARYLAND
    MASSACHUSETTS
    MICHIGAN
    MINNESOTA
    MISSISSIPPI
    MISSOURI
    MONTANA
    NEBRASKA
    NEVADA
    NEW HAMPSHIRE
    NEW JERSEY
    NEW MEXICO
    NEW YORK
    NORTH CAROLINA
    NORTH DAKOTA
    OHIO
    OKLAHOMA
    OREGON
    PENNSYLVANIA
    PUERTO RICO
    RHODE ISLAND
    SOUTH CAROLINA
    SOUTH DAKOTA
    TENNESSEE
    TEXAS
    UTAH
    VERMONT
    VIRGINIA
    WASHINGTON
    WEST VIRGINIA
    WISCONSIN
    WYOMING
    ALBERTA, CANADA
    BRITISH COLUMBIA, CANADA
    MANITOBA, CANADA
    NEW BRUNSWICK, CANADA
    NEWFOUNDLAND, CANADA
    NOVA SCOTIA, CANADA
    ONTARIO, CANADA
    PRINCE EDWARD ISLAND, CANADA
    QUEBEC, CANADA
    SASKATCHEWAN, CANADA
    YUKON, CANADA
    CANADA (FEDERAL LEVEL)

    Using the list below, select the jurisdictions in which the securities are to be offered by underwriters, dealers or sales persons or check the appropriate box

    None Checkbox not checked
    Same as the jurisdictions in which the issuer intends to offer the securities Checkbox checked
    Selected States and Jurisdictions

    ALABAMA
    ALASKA
    ARIZONA
    ARKANSAS
    CALIFORNIA
    COLORADO
    CONNECTICUT
    DELAWARE
    DISTRICT OF COLUMBIA
    FLORIDA
    GEORGIA
    HAWAII
    IDAHO
    ILLINOIS
    INDIANA
    IOWA
    KANSAS
    KENTUCKY
    LOUISIANA
    MAINE
    MARYLAND
    MASSACHUSETTS
    MICHIGAN
    MINNESOTA
    MISSISSIPPI
    MISSOURI
    MONTANA
    NEBRASKA
    NEVADA
    NEW HAMPSHIRE
    NEW JERSEY
    NEW MEXICO
    NEW YORK
    NORTH CAROLINA
    NORTH DAKOTA
    OHIO
    OKLAHOMA
    OREGON
    PENNSYLVANIA
    PUERTO RICO
    RHODE ISLAND
    SOUTH CAROLINA
    SOUTH DAKOTA
    TENNESSEE
    TEXAS
    UTAH
    VERMONT
    VIRGINIA
    WASHINGTON
    WEST VIRGINIA
    WISCONSIN
    WYOMING
    ALBERTA, CANADA
    BRITISH COLUMBIA, CANADA
    MANITOBA, CANADA
    NEW BRUNSWICK, CANADA
    NEWFOUNDLAND, CANADA
    NOVA SCOTIA, CANADA
    ONTARIO, CANADA
    PRINCE EDWARD ISLAND, CANADA
    QUEBEC, CANADA
    SASKATCHEWAN, CANADA
    YUKON, CANADA
    CANADA (FEDERAL LEVEL)

    1-A: Item 6. Unregistered Securities Issued or Sold Within One Year

    Unregistered Securities Issued or Sold Within One Year

    None Checkbox not checked

    Unregistered Securities Issued

    As to any unregistered securities issued by the issuer of any of its predecessors or affiliated issuers within one year before the filing of this Form 1-A, state:

    (a)Name of such issuer
    Medicus Pharma Ltd. 
    (b)(1) Title of securities issued
    Convertible notes
     
    (2) Total Amount of such securities issued
    5172500
    (3) Amount of such securities sold by or for the account of any person who at the time was a director, officer, promoter or principal securityholder of the issuer of such securities, or was an underwriter of any securities of such issuer.
    0 
    (c)(1) Aggregate consideration for which the securities were issued and basis for computing the amount thereof.
    $5,172,500 (principal amount of convertible notes issued)
     
    (2) Aggregate consideration for which the securities listed in (b)(3) of this item (if any) were issued and the basis for computing the amount thereof (if different from the basis described in (c)(1)).
     

    Unregistered Securities Issued

    As to any unregistered securities issued by the issuer of any of its predecessors or affiliated issuers within one year before the filing of this Form 1-A, state:

    (a)Name of such issuer
    Medicus Pharma Ltd. 
    (b)(1) Title of securities issued
    Common shares issued upon conversion of the convertible notes
     
    (2) Total Amount of such securities issued
    1308798
    (3) Amount of such securities sold by or for the account of any person who at the time was a director, officer, promoter or principal securityholder of the issuer of such securities, or was an underwriter of any securities of such issuer.
    0 
    (c)(1) Aggregate consideration for which the securities were issued and basis for computing the amount thereof.
    N/A
     
    (2) Aggregate consideration for which the securities listed in (b)(3) of this item (if any) were issued and the basis for computing the amount thereof (if different from the basis described in (c)(1)).
     

    Unregistered Securities Issued

    As to any unregistered securities issued by the issuer of any of its predecessors or affiliated issuers within one year before the filing of this Form 1-A, state:

    (a)Name of such issuer
    Medicus Pharma Ltd. 
    (b)(1) Title of securities issued
    Common Shares
     
    (2) Total Amount of such securities issued
    2922500
    (3) Amount of such securities sold by or for the account of any person who at the time was a director, officer, promoter or principal securityholder of the issuer of such securities, or was an underwriter of any securities of such issuer.
    0 
    (c)(1) Aggregate consideration for which the securities were issued and basis for computing the amount thereof.
    $5,845,000. 2,922,500 common shares issued at a price of $2.00 per share.
     
    (2) Aggregate consideration for which the securities listed in (b)(3) of this item (if any) were issued and the basis for computing the amount thereof (if different from the basis described in (c)(1)).
     

    Unregistered Securities Issued

    As to any unregistered securities issued by the issuer of any of its predecessors or affiliated issuers within one year before the filing of this Form 1-A, state:

    (a)Name of such issuer
    Medicus Pharma Ltd. 
    (b)(1) Title of securities issued
    Stock Options
     
    (2) Total Amount of such securities issued
    505000
    (3) Amount of such securities sold by or for the account of any person who at the time was a director, officer, promoter or principal securityholder of the issuer of such securities, or was an underwriter of any securities of such issuer.
    0 
    (c)(1) Aggregate consideration for which the securities were issued and basis for computing the amount thereof.
    N/A
     
    (2) Aggregate consideration for which the securities listed in (b)(3) of this item (if any) were issued and the basis for computing the amount thereof (if different from the basis described in (c)(1)).
     

    Unregistered Securities Act

    (d) Indicate the section of the Securities Act or Commission rule or regulation relied upon for exemption from the registration requirements of such Act and state briefly the facts relied upon for such exemption
    These securities were sold in reliance on Regulation S promulgated under the Securities Act, Regulation D under the Securities Act, Rule 701 under the Securities Act or pursuant to Section 4(a)(2) of the Securities Act.
     
    Get the next $MDCX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDCX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MDCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Smith Andrew Alasdair

    4 - Medicus Pharma Ltd. (0001997296) (Issuer)

    12/18/25 4:10:07 PM ET
    $MDCX

    SEC Form 4 filed by Director Rodgers Cathy Mcmorris

    4 - Medicus Pharma Ltd. (0001997296) (Issuer)

    12/18/25 4:09:52 PM ET
    $MDCX

    SEC Form 4 filed by Director Raju Ajay

    4 - Medicus Pharma Ltd. (0001997296) (Issuer)

    12/18/25 4:09:38 PM ET
    $MDCX

    $MDCX
    SEC Filings

    View All

    SEC Form EFFECT filed by Medicus Pharma Ltd.

    EFFECT - Medicus Pharma Ltd. (0001997296) (Filer)

    2/5/26 12:15:17 AM ET
    $MDCX

    SEC Form S-3 filed by Medicus Pharma Ltd.

    S-3 - Medicus Pharma Ltd. (0001997296) (Filer)

    1/30/26 4:31:21 PM ET
    $MDCX

    Amendment: SEC Form SCHEDULE 13G/A filed by Medicus Pharma Ltd.

    SCHEDULE 13G/A - Medicus Pharma Ltd. (0001997296) (Subject)

    1/5/26 8:35:41 PM ET
    $MDCX

    $MDCX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

    Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix® as a first in class market product for Acute Urinary Retention Relapse prevention (AURr) and best in class for prostate cancer patients with high CV risk collectively representing ~US$6 billion in potential market opportunity PHILADELPHIA, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that its su

    1/22/26 7:30:00 AM ET
    $MDCX

    Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

    PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce it will ring the Nasdaq Opening Bell at the Nasdaq MarketSite in New York's Times Square on Thursday, January 22, 2026, in recognition of the Company's one-year anniversary as a Nasdaq-listed company. Since its Nasdaq listing, Medicus has remained focused on disciplined execution across its streamlined clinical portfolio, advancing select therapeutic assets through Phase 2 proof-of-concept and purs

    1/20/26 7:30:00 AM ET
    $MDCX

    Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

    PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that detailed clinical data on Teverelix, its long-acting gonadotropin-releasing hormone (GnRH) antagonist, have been accepted for e-Poster presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026, to be held April 22–24 in Las Vegas, Nevada. The Company's accepted abstract: "Evaluation of Teverelix, a Long-Acting GnRH Antagonist: Pharmacokinetics, Pharmacodyn

    1/12/26 7:30:00 AM ET
    $MDCX

    $MDCX
    Leadership Updates

    Live Leadership Updates

    View All

    Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

    TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab

    11/18/24 7:30:00 AM ET
    $GSK
    $MDCX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDCX
    Financials

    Live finance-specific insights

    View All

    Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

    Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix® as a first in class market product for Acute Urinary Retention Relapse prevention (AURr) and best in class for prostate cancer patients with high CV risk collectively representing ~US$6 billion in potential market opportunity PHILADELPHIA, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that its su

    1/22/26 7:30:00 AM ET
    $MDCX

    Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

    PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce it will ring the Nasdaq Opening Bell at the Nasdaq MarketSite in New York's Times Square on Thursday, January 22, 2026, in recognition of the Company's one-year anniversary as a Nasdaq-listed company. Since its Nasdaq listing, Medicus has remained focused on disciplined execution across its streamlined clinical portfolio, advancing select therapeutic assets through Phase 2 proof-of-concept and purs

    1/20/26 7:30:00 AM ET
    $MDCX

    Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

    PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that detailed clinical data on Teverelix, its long-acting gonadotropin-releasing hormone (GnRH) antagonist, have been accepted for e-Poster presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026, to be held April 22–24 in Las Vegas, Nevada. The Company's accepted abstract: "Evaluation of Teverelix, a Long-Acting GnRH Antagonist: Pharmacokinetics, Pharmacodyn

    1/12/26 7:30:00 AM ET
    $MDCX